Dabigatran (BIBR-1048) etexilate - Moligand™, 10mM in DMSO , CAS No.211915-06-9

CAS: 211915-06-9 Cat. No.: D408215 Molecular Weight: 627.73 PubChem CID: 6445226

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Dabigatran (BIBR-1048) etexilate Dabigatran Etexilate (BIBR-1048) is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombi
In vitro

Dabigatran selectively and reversibly inhibits human thrombin (Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC50: 10 nM), while showing no inhibitory effect on other platelet-stimulating agents. Dabigatran selectively and reversibly inhibits human thrombin (Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC50: 10 nM), while showing no inhibitory effect on other platelet-stimulating agents. Dabigatran inhibits thrombin generation in platelet-poor plasma (PPP) with IC50 of 0.56 μM, measured as the endogenous thrombin potential (ETP). Dabigatran demonstrates concentrationdependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 μM, respectively. ^[1]

In vivo

Dabigatran prolongs the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dabigatran etexilate (20 mg/kg, orally) produces less prolongation of K value and less decreases in angle and maximum amplitude than enoxaparin in swine. Dabigatran (0.01-0.1 mg/kg) reduces thrombus formation dose-dependently, with an ED50 (50% of the effective dose) of 0.033 mg/kg and complete inhibition at 0.1 mg/kg. Dabigatran etexilate (5-30 mg/kg) inhibits thrombus formation in a dose- and time-dependent manner, with maximum inhibition within 30 min of pretreatment, suggesting a rapid onset of action.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥97%

Specifications

Synonyms

(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Dabigatran Etexilate (BIBR-1048) is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR

Names and Identifiers

• Isomeric SMILES: CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\N
• PubChem CID: 6445226
• Molecular Weight: 627.73

Chemical and Physical Properties

• Solubility: Solubility (25°C) In vitro DMSO: 100 mg/mL (128.05 mM); Water: Insoluble; Ethanol: Insoluble
• Melt Point(°C): 131 °C

References

1. Hui Guo, Lili Guo, Jianwei Yu, Fengju Zhao, Wei Yang, Jiaxin Li, Hanqi Chen, Junqing Qian.  (2024)  Magnetic nanoparticles immobilized thrombin ligand fishing to screen thrombin inhibitors in natural products.  JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,      [PMID:38513498] [10.1016/j.jpba.2024.116110]

2. Oushan Tang, Shitong Wang, Guanguan Qiu, Majun Zhang, Liping Ling, Yan Zhang, Meiqun Guo, Chunxia Shen, Bin Quan, Hongjie Lang, Qing Shen, Keyun Cheng.  (2025)  Optimized simultaneous detection of multiple Oral anticoagulants in plasma using enhanced matrix removal-lipid solid-phase extraction and LC-MS/MS.  Results in Chemistry,      [PMID:] [10.1016/j.rechem.2025.103011]

3. Jingfei Wang, Shuting Li, Liwu Liu, Fukai Liu, Cheng Lin, Yanju Liu, Jinsong Leng.  (2026)  4D-Printed Intelligent Reconfigurable Occluder With Anti-Thrombotic and Rapid-Repairing Capabilities for Patent Foramen Ovale.  Advanced Healthcare Materials,      [PMID:41645865] [10.1002/adhm.202505214]